Gengraf

Heymann Nephritis, Lupus Nephritis, Nephrotic Syndrome + 30 more

Treatment

27 FDA approvals

20 Active Studies for Gengraf

What is Gengraf

Cyclosporine

The Generic name of this drug

Treatment Summary

Cyclosporine is a medication used to prevent organ transplant rejection and treat inflammatory and autoimmune conditions. It is derived from a fungus called Beauveria nivea and was first manufactured by Sandoz in 1983. It is now available in various brands, such as Novartis, which was formerly known as Sandoz.

Sandimmune

is the brand name

image of different drug pills on a surface

Gengraf Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sandimmune

Cyclosporine

1983

68

Approved as Treatment by the FDA

Cyclosporine, also known as Sandimmune, is approved by the FDA for 27 uses which include Prophylaxis against heart transplant rejection and Heart Transplant Rejection .

Prophylaxis against heart transplant rejection

Heart Transplant Rejection

Therapeutic immunosuppression

Chronic Graft Versus Host Disease

Glomerulosclerosis, Focal Segmental

Helps manage Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis (FSGS)

Helps manage Focal Segmental Glomerulosclerosis (FSGS)

Prophylaxis against graft versus host disease

Liver

Liver Transplant Rejection

Heymann Nephritis

Helps manage Glomerulonephritis, Membranous

Glomerulosclerosis

Helps manage Glomerulosclerosis

severe, active Rheumatoid arthritis

Helps manage severe, active Rheumatoid arthritis

Patients who do not adequately respond to methotrexate alone

Used to treat Patients who do not adequately respond to methotrexate alone in combination with Methotrexate

Kidney Transplant Rejection

Steroid Resistant Nephrotic Syndrome

Helps manage Steroid Resistant Nephrotic Syndrome

Steroid Dependent Nephrotic Syndrome

Helps manage Steroid Dependent Nephrotic Syndrome

severe, recalcitrant Plaque psoriasis

Helps manage severe, recalcitrant Plaque psoriasis

Not responsive to other therapy

Helps manage Not responsive to other therapy

Bone Marrow Transplantation

Prophylaxis against stem cell transplant rejection

Transplantation

Rheumatoid Arthritis

Helps manage severe, active Rheumatoid arthritis

Nephrotic Syndrome

Helps manage Nephrotic Syndrome

Bone Marrow

Kidney Transplantation

Nephrotic Syndrome

Helps manage Steroid Resistant Nephrotic Syndrome

Nephrotic Syndrome

Helps manage Steroid Dependent Nephrotic Syndrome

Effectiveness

How Gengraf Affects Patients

Cyclosporine is a drug used to suppress the activity of the immune system, helping to prolong the success of organ and bone marrow transplants. It also helps to prevent and control serious immune-related reactions, such as allograft rejection, graft versus host disease, and autoimmune disease. However, it can cause certain side effects, such as excessive hair growth, gum enlargement, increased cholesterol levels, and in some cases, kidney damage.

How Gengraf works in the body

Cyclosporine is a drug that stops inflammation by blocking the activation of T cells. It does this by binding to a receptor inside cells and forming a complex. This complex then prevents calcineurin from activating a certain factor, called NF-AT, which triggers the production of inflammatory chemicals like cytokines. By stopping this process, cyclosporine can reduce inflammation and stop T cell activation or growth. It also lowers levels of other substances associated with T cell function and thymocyte development.

When to interrupt dosage

The suggested dosage of Gengraf is contingent upon the diagnosed condition, such as Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The measure of dosage is dependent on the mode of administration (e.g. Liquid - Intravenous or Ophthalmic; Topical) listed in the table below.

Condition

Dosage

Administration

Nephrotic Syndrome

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Nephrotic Syndrome

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Prophylaxis against stem cell transplant rejection

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Patients who do not adequately respond to methotrexate alone

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Bone Marrow

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Conjunctivitis, Allergic

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Organ Transplantation

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Not responsive to other therapy

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Heymann Nephritis

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Rosacea

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Ulcerative Colitis

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Juvenile arthritis

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Cystitis, Interstitial

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Disease

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Bone Marrow Transplantation

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Chronic Graft Versus Host Disease

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Transplantation

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Dry Eye Syndromes

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Therapeutic immunosuppression

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Nephrotic Syndrome

0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %

, Emulsion, Emulsion - Ophthalmic, Ophthalmic, Solution - Oral, Oral, Solution, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Oral, Capsule, Intravenous, Injection, solution - Intravenous, Injection, solution, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic; Topical, Ophthalmic; Topical, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical, Injection - Intravenous, Topical, Liquid - Topical

Warnings

Gengraf has six contraindications. It should not be taken simultaneously with any of the conditions noted in the following table.

Gengraf Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Psoriasis

Do Not Combine

Abnormal Renal Function

Do Not Combine

Hypertensive disease

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Cyclosporine may interact with Pulse Frequency

There are 20 known major drug interactions with Gengraf.

Common Gengraf Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Cyclosporine.

Aliskiren

Major

The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Cyclosporine.

Gengraf Toxicity & Overdose Risk

The lowest toxic dose of cyclosporine in rats is 1480 mg/kg and the toxicity level for humans is 12 mg/kg. Symptoms of an overdose include nausea, flushing, trembling, dizziness, vomiting, and loss of appetite. These symptoms usually go away within a day, but the feeling of increased body girth may take up to two weeks to resolve. Treatment for cyclosporine overdose should include forced vomiting and stomach pumping within two hours of ingestion, as dialysis and charcoal hemoperfusion are not effective methods of removing the drug from the body.

image of a doctor in a lab doing drug, clinical research

Gengraf Novel Uses: Which Conditions Have a Clinical Trial Featuring Gengraf?

81 clinical trials are being conducted to investigate the potential of Gengraf to alleviate Chronic Graft Versus Host Disease, Kidney Diseases and Ulcerative Colitis.

Condition

Clinical Trials

Trial Phases

Therapeutic immunosuppression

0 Actively Recruiting

Rheumatoid Arthritis

0 Actively Recruiting

Bone Marrow

1 Actively Recruiting

Early Phase 1

severe, recalcitrant Plaque psoriasis

0 Actively Recruiting

Nephrotic Syndrome

5 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Disease

0 Actively Recruiting

Prophylaxis against graft versus host disease

0 Actively Recruiting

Liver

0 Actively Recruiting

Heymann Nephritis

3 Actively Recruiting

Phase 2, Phase 1

Glomerulosclerosis

0 Actively Recruiting

Prophylaxis against heart transplant rejection

0 Actively Recruiting

Organ Transplantation

0 Actively Recruiting

Excessive tearing

0 Actively Recruiting

Transplantation

0 Actively Recruiting

Lupus Nephritis

24 Actively Recruiting

Phase 3, Phase 2, Phase 1, Phase 4

Not responsive to other therapy

0 Actively Recruiting

Kidney Transplantation

0 Actively Recruiting

Glomerulosclerosis, Focal Segmental

10 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4

Uveitis

3 Actively Recruiting

Not Applicable, Phase 3

Nephrotic Syndrome

0 Actively Recruiting

Gengraf Reviews: What are patients saying about Gengraf?

5

Patient Review

11/19/2008

Gengraf for Prevent Kidney Transplant Rejection

I received a kidney transplant in 1999 and, overall, I think it was successful.

5

Patient Review

1/22/2009

Gengraf for Treatment to Prevent Reaction After Bone Marrow Transplant

I've been using this medication for less than a year and it's doing a great job. I never had any difficulty with nausea, and my kidneys are tested regularly and doing fine so far.

5

Patient Review

1/23/2008

Gengraf for Prevention of Liver Transplant Rejection

I have been on Genfraf for 5 years and was wondering what could cause my level to drop low when I take 2 doses BID? I would like to know how long it takes gengraf to get through my system, and how long I would take it after vomiting?

5

Patient Review

7/15/2009

Gengraf for Prevention of Liver Transplant Rejection

I received a liver transplant in December 2002 and was prescribed this medication 2-3 months afterwards. I have had no side effects or rejections, and it has kept me healthy overall. The only downside is that it is quite expensive; however, the capsules are easy to take. I believe it raised my blood pressure slightly, but I take Norvasc 5mg once daily to counteract that. All of my blood work has been normal thus far while taking this drug.

3.7

Patient Review

10/24/2012

Gengraf for Prevent Kidney Transplant Rejection

After losing my insurance, I had to switch from Neoral to Gengraf. I feel like Gengraf doesn't work as well for me; I'm constantly in pain and I don't know if it's the medication or not.

2.7

Patient Review

2/24/2012

Gengraf for Prevent Kidney Transplant Rejection

I switched to Gengraf from another Cyclosporine modulator a few months ago, and I've developed mouth and throat sores. Is this a common side effect?

1

Patient Review

11/30/2009

Gengraf for Prevent Kidney Transplant Rejection

I do not take this medication, but I know someone who does. They've been taking it for at least three years, even though it's expired. I'm wondering if there are any health risks associated with taking expired medication. Can anyone provide some insight?

Patient Q&A Section about gengraf

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Neoral and GENGRAF?

"Gengraf is equivalent to Neoral in terms of efficacy. Additionally, Gengraf is well tolerated and can be used interchangeably with Neoral in stable Chinese renal allograft recipients."

Answered by AI

Is GENGRAF an immunosuppressant?

"GENGRAF is a drug that suppresses the immune system, making the body more susceptible to infection and disease. When taken with other immunosuppressant drugs, the effects are amplified."

Answered by AI

Is GENGRAF brand or generic?

"Gengraf is an immunosuppressant drug used to prevent organ rejection in people who have undergone kidney, liver, or heart transplant surgery. It is also sometimes used to treat severe cases of psoriasis or rheumatoid arthritis. A generic form of Gengraf is also available."

Answered by AI

What is GENGRAF used for?

"Cyclosporine capsules and oral solution are prescription medicines used to help prevent organ rejection in people who have received a kidney, liver, or heart transplant."

Answered by AI

Clinical Trials for Gengraf

Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

Treatment for T-Cell Lymphoma

18+
All Sexes
Columbus, OH

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Phase 2
Recruiting

Ohio State University Comprehensive Cancer Center

Jonathan Brammer, MD

Incyte Corporation

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Meal Macronutrients for Blood Fat Levels

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: * A resting metabolic test captures the air they exhale and measures how much energy they use at rest. * A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. * A Fibroscan is a special type of ultrasound of the liver. * A body surface scan uses lasers to measure the total area of the body. * A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Have you considered Gengraf clinical trials?

We made a collection of clinical trials featuring Gengraf, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Pain Mechanisms for Juvenile Arthritis

9 - 17
All Sexes
St Louis, MO

Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in children. The main symptoms of JIA, which are often the primary focus of treatment, include joint swelling, stiffness, and tenderness. Additional symptoms can include malaise, fatigue, and pain. However, the exact mechanisms contributing to pain are not yet fully understood. Participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed. In addition, demographic, social, pubertal maturation, and behavioral and psychological factors will be collected via questionnaires. A saliva sample and/or blood draw may occur for the analysis of various immune factors and sex hormones. If a joint aspiration is done as part of their standard of care, we will request a sample of the synovial fluid for analyses of immune, hormonal and/or genetic factors. Participants will have the option to participate in additional optional follow-up study visits (every 3 months, up to 1 year) and to complete monthly surveys asking about their juvenile arthritis.

Recruiting
Has No Placebo

Washington University School of Medicine

Hadas Nahman-Averbuch, PhD

Image of Allied Biomedical Research Institute in Miami, United States.

Cenerimod for Lupus Nephritis

18 - 75
All Sexes
Miami, FL

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.

Phase 3
Waitlist Available

Allied Biomedical Research Institute

Clinical Trials

Viatris Innovation GmbH

Image of Astera Cancer Care in East Brunswick, United States.

ALLO-329 for Lupus

18 - 69
All Sexes
East Brunswick, NJ

This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R).

Phase 1
Recruiting

Astera Cancer Care (+1 Sites)

Allogene Study Director

Allogene Therapeutics

Have you considered Gengraf clinical trials?

We made a collection of clinical trials featuring Gengraf, we think they might fit your search criteria.
Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Emapalumab for Graft-versus-Host Disease

18 - 75
All Sexes
Duarte, CA

This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.

Phase 1
Waitlist Available

City of Hope Medical Center

Amandeep Salhotra

Have you considered Gengraf clinical trials?

We made a collection of clinical trials featuring Gengraf, we think they might fit your search criteria.
Go to Trials